Role of FGF23 in Pediatric Hypercalciuria

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Feb 20

PMID 29457024

Citations 1

Authors

Maria Goretti Moreira Guimaraes Penido

Marcelo de Sousa Tavares

Uri Saggie Alon

Affiliations

Soon will be listed here.

Abstract

Background: This study explored the possible role of FGF23 in pediatric hypercalciuria.

Methods: Plasma FGF23 was measured in 29 controls and 58 children and adolescents with hypercalciuria: 24 before treatment (Pre-Treated) and 34 after 6 months of treatment (Treated). Hypercalciuric patients also measured serum PTH hormone, 25(OH)vitD, phosphate, calcium, creatinine, and 24 h urine calcium, phosphate, and creatinine.

Results: There were no differences in age, gender, ethnicity, or body mass index either between controls and patients, or between Pre-Treated and Treated patients. Median plasma FGF23 in controls was 72 compared with all patients, 58 RU/mL ( = 0.0019). However, whereas FGF23 in Pre-Treated patients, 73 RU/mL, was not different from controls, in Treated patients it was 50 RU/mL, significantly lower than in both controls ( < 0.0001) and Pre-Treated patients ( = 0.02). In all patients, there was a correlation between FGF23 and urinary calcium ( = 0.325; = 0.0014). Treated patients had significantly lower urinary calcium ( < 0.0001), higher TP/GFR ( < 0.001), and higher serum phosphate ( = 0.007) versus Pre-Treated patients.

Conclusions: Pharmacological treatment of hypercalciuric patients resulted in significantly lower urinary calcium excretion, lower serum FGF23, and elevated TP/GFR and serum phosphate concentration, without significant changes in PTH. Further studies are indicated. This trial is registered with Clinical Registration Number RBR 8W27X5.

Citing Articles

Beyond kidney stones: Why pediatricians should worry about hypercalciuria.

Penido M, Tavares M World J Clin Pediatr. 2021; 10(6):137-150.

PMID: 34868890 PMC: 8603641. DOI: 10.5409/wjcp.v10.i6.137.

References

Penido M, Lima E, Marino V, Tupinamba A, Franca A, Souto M . Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis. Pediatr Nephrol. 2003; 18(2):133-9. DOI: 10.1007/s00467-002-1036-6. View

Favus M, Karnauskas A, Parks J, Coe F . Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab. 2004; 89(10):4937-43. DOI: 10.1210/jc.2004-0412. View

Alon U, Berenbom A . Idiopathic hypercalciuria of childhood: 4- to 11-year outcome. Pediatr Nephrol. 2000; 14(10-11):1011-5. DOI: 10.1007/s004670050064. View

Osorio A, Alon U . The relationship between urinary calcium, sodium, and potassium excretion and the role of potassium in treating idiopathic hypercalciuria. Pediatrics. 1997; 100(4):675-81. DOI: 10.1542/peds.100.4.675. View

Menon V, Moyses R, Gomes S, Carvalho A, Jorgetti V, Heilberg I . Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers. Clin J Am Soc Nephrol. 2014; 9(7):1263-70. PMC: 4078962. DOI: 10.2215/CJN.10030913. View

Alon U, Zimmerman H, Alon M . Evaluation and treatment of pediatric idiopathic urolithiasis-revisited. Pediatr Nephrol. 2004; 19(5):516-20. DOI: 10.1007/s00467-004-1422-3. View

Asplin J, Donahue S, Kinder J, Coe F . Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int. 2006; 70(8):1463-7. DOI: 10.1038/sj.ki.5001778. View

Goretti Penido M, Alon U . Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012; 27(11):2039-2048. PMC: 3461213. DOI: 10.1007/s00467-012-2175-z. View

Rendina D, Mossetti G, DE Filippo G, Cioffi M, Strazzullo P . Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab. 2005; 91(3):959-63. DOI: 10.1210/jc.2005-1606. View

10.

Telci D, Dogan A, Ozbek E, Polat E, Simsek A, Cakir S . KLOTHO gene polymorphism of G395A is associated with kidney stones. Am J Nephrol. 2011; 33(4):337-43. DOI: 10.1159/000325505. View

11.

Hellerstein S, Simon S, BERENBOM M, Erwin P, Nickell E . Creatinine excretion rates for renal clearance studies. Pediatr Nephrol. 2001; 16(8):637-43. DOI: 10.1007/s004670100622. View

12.

ADAMS N, Gray R, LEMANN Jr J, Cheung H . Effects of calcitriol administration on calcium metabolism healthy men. Kidney Int. 1982; 21(1):90-7. DOI: 10.1038/ki.1982.13. View

13.

Penido M, Srivastava T, Alon U . Pediatric primary urolithiasis: 12-year experience at a Midwestern Children's Hospital. J Urol. 2012; 189(4):1493-7. DOI: 10.1016/j.juro.2012.11.107. View

14.

Chang Q, Hoefs S, van der Kemp A, Topala C, Bindels R, Hoenderop J . The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005; 310(5747):490-3. DOI: 10.1126/science.1114245. View

15.

Worcester E, Coe F . Evidence for altered renal tubule function in idiopathic calcium stone formers. Urol Res. 2010; 38(4):263-9. PMC: 3641150. DOI: 10.1007/s00240-010-0299-9. View

16.

Sakhaee K, Maalouf N, Kumar R, Pasch A, Moe O . Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2010; 79(4):393-403. PMC: 3088506. DOI: 10.1038/ki.2010.473. View

17.

Srivastava T, Schwaderer A . Diagnosis and management of hypercalciuria in children. Curr Opin Pediatr. 2009; 21(2):214-9. DOI: 10.1097/MOP.0b013e3283223db7. View

18.

Taylor E, Fung T, Curhan G . DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009; 20(10):2253-9. PMC: 2754098. DOI: 10.1681/ASN.2009030276. View

19.

Prie D, Ravery V, Boccon-Gibod L, Friedlander G . Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int. 2001; 60(1):272-6. DOI: 10.1046/j.1523-1755.2001.00796.x. View

20.

Scales Jr C, Tasian G, Schwaderer A, Goldfarb D, Star R, Kirkali Z . Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. Clin J Am Soc Nephrol. 2016; 11(7):1305-1312. PMC: 4934851. DOI: 10.2215/CJN.13251215. View